Shintaro Shichinohe

Dr. Shintaro Shichinohe


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
SSShintaro Shichinohe
Shintaro Shichinohe
TWTokiko Watanabe
Tokiko Watanabe
The numerous influenza infections that occur every year present a major public health problem. Influenza vaccines are important for the prevention of the disease; however, their effectiveness against infection can be suboptimal. Particularly in the elderly, immune induction can be insufficient, and the vaccine efficacy against infection is usually lower than that in young adults. Vaccine efficacy can be improved by the addition of adjuvants, and an influenza vaccine with an oil-in-water adjuvant MF59, FLUAD, has been recently licensed in the United States and other countries for persons aged 65 years and older. Although the adverse effects of adjuvanted vaccines have been a concern, many adverse effects of currently approved adjuvanted influenza vaccines are mild and acceptable, given the overriding benefits of the vaccine. Since sufficient immunity can be induced with a small amount of vaccine antigen in the presence of an adjuvant, adjuvanted vaccines promote dose sparing and the prompt preparation of vaccines for pandemic influenza. Adjuvants not only enhance the immune response to antigens but can also be effective against antigenically different viruses. In this narrative review, we provide an overview of influenza vaccines, both past and present, before presenting a discussion of adjuvanted influenza vaccines and their future.

31 March 2023 in Japanese Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SSShintaro Shichinohe
Shintaro Shichinohe
YSYasuteru Sakurai
Yasuteru Sakurai
DHDaisuke Hayasaka
Daisuke Hayasaka
EYEri Yamada
Eri Yamada
KSKatsuaki Shinohara
Katsuaki Shinohara
KNKensuke Nakajima
Kensuke Nakajima
Biosafety Level 4 (BSL-4) laboratories are necessary to study microorganisms that are highly pathogenic to humans and have no prevention or therapeutic measures. Currently, most BSL-4 facilities have suit-type laboratories to conduct experiments on highly pathogenic microorganisms. In 2021, the first Japanese suit-type BSL-4 laboratory was constructed at Nagasaki University. Positive pressure protection suit (PPPS) is a primary barrier that protect and isolate laboratory workers from pathogens and the laboratory environment. Here, we developed a novel PPPS originally designed to be used in the Nagasaki BSL-4 laboratory. We modified several parts of the domestic chemical protective suit, including its front face shield, cuff, and air supply hose, for safe handling of microbiological agents. The improved suit, PS-790BSL4-AL, showed resistance to several chemicals, including quaternary ammonium disinfectant, and did not show any permeation against blood and phages. To validate the suit’s integrity, we also established an airtight test that enabled the elimination of individual differences for quantitative testing. Thus, our developed suit is sufficient as a primary barrier and allows for the safe handling of pathogens in our new BSL-4 laboratory.

6 January 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
SSShintaro Shichinohe
Shintaro Shichinohe
THTakahiro Hiono
Takahiro Hiono
YIYasushi Itoh
Yasushi Itoh
KTKosuke Takada
Kosuke Takada
YKYurie Kida
Yurie Kida
TWTokiko Watanabe
Tokiko Watanabe
H5N1 high pathogenicity avian influenza virus (HPAIV) has spread in wild birds and poultry worldwide. H5N1 HPAIV belonging to the currently predominant clade 2.3.4.4b has infected not only birds but also mammals (wild and domestic animals), with several human infections also being reported, raising concerns for public health. In 2022, a clade 2.3.4.4b H5N1 HPAIV strain, A/Ezo red fox/Hokkaido/1/2022 (H5N1; Fox/Hok/1/22), was isolated from an Ezo red fox ( Vulpes vulpes schrencki ) in Hokkaido, Japan; this was the first reported case of clade 2.3.4.4b H5N1 HPAIV isolation from a mammalian species in Japan. Several amino acid substitutions in the PB2 protein play an important role in the adaptation of avian influenza viruses to mammals, but Fox/Hok/1/22 PB2 does not have any of these well-known mammalian-adapting PB2 substitutions. Here, we investigated the biological properties of Fox/Hok/1/22 in a mouse model and found that this virus was highly virulent in mice and replicated well in multiple organs, including the lungs and brain. We then examined whether viruses isolated from these organs acquired known mammalian-adapting PB2 amino acid substitutions, such as PB2 E627K. Deep sequencing analysis of viral RNA from mouse brain and lungs revealed that virus with PB2-627E was predominant in three of four mice, whereas the PB2-627K substitution was predominant in one mouse. These results indicate that Fox/Hok/1/22 is highly virulent in mice despite lacking known PB2 substitutions involved in mammalian adaptation. IMPORTANCE: The H5N1 avian influenza virus has caused severe disease in birds worldwide and is now spreading to mammals, including humans. In 2022, this virus was detected for the first time in an Ezo red fox in Japan. To understand its potential impact on mammals, we studied this virus in mice and found that it caused severe illness, spreading to multiple organs, including the lungs and brain. Surprisingly, despite lacking genetic mutations typically associated with mammalian adaptation, the virus was highly virulent in mice. This finding suggests that the H5N1 virus may pose a greater threat to mammals, including humans, than previously thought. Given their continued spread among wild and domestic animals, our findings underscore the urgent need to monitor how recent H5N1 viruses behave in mammals.

2 November 2025 in bioRxiv
Verified
Preprint
Open access
SSShintaro Shichinohe
Shintaro Shichinohe
HSHikaru Sugimoto
Hikaru Sugimoto
MYMasako Yamasaki
Masako Yamasaki
RHRina Hashimoto
Rina Hashimoto
TMTatsuru Morita
Tatsuru Morita
TWTokiko Watanabe
Tokiko Watanabe
Summary: The H5N1 high pathogenicity avian influenza virus (HPAIV) of clade 2.3.4.4b, which spreads globally via wild birds, has become a major public health concern because it can infect a variety of mammals, including humans. In 2024, infection of dairy cattle with H5N1 HPAIV clade 2.3.4.4b was confirmed in the United States, and subsequent human cases were reported. Although these viruses are highly pathogenic in animal models, human infections have generally been mild, revealing a striking discrepancy. Here, we characterized the cattle-derived human H5N1 isolate A/Texas/37/2024 (TX37-H5N1) using three-dimensional human respiratory organoids derived from induced pluripotent stem (iPS) cells. Despite efficient replication, TX37-H5N1 induced minimal interferon and inflammatory cytokine responses. Bulk and single-cell RNA sequencing revealed reduced STAT1-mediated transcriptional activity in TX37-H5N1-infected organoids compared to the historic H5N1 human isolate A/Vietnam/1203/2004. These findings suggest that TX37-H5N1 fails to trigger the strong innate responses, including robust cytokine production, that are typically associated with severe H5N1 disease and are thought to contribute to cytokine storm-medicated pathogenesis. This attenuated response may help explain the discrepancy between the high pathogenicity of TX37-H5N1 in animal models and its mild clinical presentation in humans. While zoonotic influenza risk is often assessed using cell lines or animal models, our study highlights the value of using human respiratory organoids to evaluate human-specific virus-host interactions. This platform provides a complementary tool for assessing the risk of emerging avian influenza viruses. Highlights: Human respiratory organoids were used to model zoonotic B3.13 H5N1 infections. A cattle-derived human isolate, TX37-H5N1, replicated more efficiently than historical VN1203-H5N1. TX37-H5N1 suppressed STAT–IRF-mediated innate immune responses. TX37-H5N1 was sensitive to baloxavir and oseltamivir but less sensitive to favipiravir. Human respiratory organoids offer a complementary platform for zoonotic influenza risk assessment. In brief: Our study used human iPSC-derived respiratory organoids to investigate the mild clinical presentation of zoonotic B3.13 H5N1 viruses. We found that TX37-H5N1 replicates efficiently but suppresses innate immune responses, providing mechanistic insight into species-specific pathogenesis and highlighting the utility of human organoids for zoonotic risk assessment.

1 December 2025 in Microbiology and Immunology
Verified
Journal Article
Open access
NKNantaporn Kaewaroon
Nantaporn Kaewaroon
SYSara Yoshimoto
Sara Yoshimoto
LMLuthfi Muawan
Luthfi Muawan
SSShintaro Shichinohe
Shintaro Shichinohe
TWTokiko Watanabe
Tokiko Watanabe
Influenza A and B viruses cause annual epidemics and continue to pose global public health concerns. The most effective approach to preventing or mitigating the severity of influenza is vaccination. Inactivated split influenza HA vaccines are commonly used worldwide due to their strong safety profile and broad range of target groups; however, their efficacy is suboptimal, especially in the elderly. Adjuvants are used to enhance the effectiveness of some influenza vaccines, but few adjuvants have been approved for human vaccines. Previously, we identified hydroxypropyl cellulose as a promising adjuvant for the split influenza HA vaccine for the 2015–2016 and 2016–2017 influenza seasons. Here, we evaluated whether hydroxypropyl cellulose could enhance the efficacy of the quadrivalent split HA vaccine for the 2023–2024 influenza season, which contains the HA proteins of A/Victoria/4897/2022 (H1N1)pdm09 and three other strains. Using a mouse model, we performed immunogenicity studies and assessed protective efficacy against challenges with homologous and heterologous H1N1pdm09 virus strains. We found that hydroxypropyl cellulose in combination with the HA vaccine generated higher virus‐specific IgG antibody titers compared to the vaccine alone. The adjuvanted vaccine provided complete protection against homologous challenge and enhanced viral clearance from respiratory organs. Notably, the adjuvanted vaccine demonstrated cross‐protective efficacy against heterologous H1N1pdm09 virus challenge, improving survival rates compared to vaccine alone. Our results demonstrate that hydroxypropyl cellulose has potential as an adjuvant for current seasonal influenza vaccines.

24 March 2026 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
SSShintaro Shichinohe
Shintaro Shichinohe
SIShinji Izumiyama
Shinji Izumiyama
YTYoshihiro Takaki
Yoshihiro Takaki
MHMiho Hirai
Miho Hirai
SUSyun-Ichi Urayama
Syun-Ichi Urayama
MKMakoto Kazama
Makoto Kazama